# FDA 483 - L'Oreal Usa, Inc. - April 01, 2026

Source: https://www.keypedia.com/records/483/loreal-usa-inc/e1b0f626-de17-497b-8b91-2a3bf3760546

> FDA 483 for L'Oreal Usa, Inc. on April 01, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: L'Oreal Usa, Inc.
- Inspection Date: 2026-04-01
- Product Type: drugs
- Office Name: FDA District Office — Cincinnati, Ohio
- Summary: An FDA inspection of L'Oreal Usa, Inc. in Florence, KY, an OTC drug manufacturer, revealed significant deficiencies in material control and quality unit procedures. Observations included inadequate storage and control of drug labels, insufficient segregation of rejected materials, and a lack of written procedures for the quality control unit, including OOS investigations and batch record review. These issues pose risks of product mix-ups and compromised quality.

## Related Documents

- [483 - 2022-09-30](https://www.keypedia.com/records/483/loreal-usa-inc/0355a2e3-a347-44a6-8214-fbfa04a77427)

## Related Officers

- [WenNing Chan](https://www.keypedia.com/people/wenning-chan/973bf578-405d-46cf-b09e-254d6db07c08)

Company: https://www.keypedia.com/companies/loreal-usa-inc/1636dd78-8b8b-478b-aa38-26e6d172ca69

Office: https://www.keypedia.com/offices/fda-district-office-cincinnati-ohio/b4972fd9-9db9-4cc6-9a4c-0146959c9d74